Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioma 3Glioblastoma 3Lung Neoplasms 2Astrocytoma 2Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma 1Ependymoma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 41Radiotherapy 15Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 10Bevacizumab 10Irinotecan 9Radiation 8Nivolumab 7Carmustine 7Specimen Handling 6Radiosurgery 6Carboplatin 6ribociclib 5O(6)-benzylguanine 5Imiquimod 5IL13-PE38 5Flucytosine 5Filgrastim 5Erlotinib Hydrochloride 5Cyclophosphamide 5Aminolevulinic Acid 5vandetanib 4sargramostim 4Topotecan 4Lomustine 4Imatinib Mesylate 4Etoposide 4Craniotomy 4vocimagene amiretrorepvec 3temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Glioma × Valacyclovir × Clear all
NCT03576612 2025-02-14

GMCI

Candel Therapeutics, Inc.

Phase 1 Completed
41 enrolled
CNS

Glioblastoma, Glioma

NCT00634231 2023-08-25

A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

Candel Therapeutics, Inc.

Phase 1 Completed
8 enrolled
CNS

Astrocytoma, Ependymoma, Glioblastoma, Glioma

NCT00751270 2023-08-25

BrTK01

Candel Therapeutics, Inc.

Phase 1 Completed
15 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡